title: Marked regression of pulmonary rheumatoid nodules under etanercept therapy.
authors.affiliation: Department of Pneumology, Henri Mondor Teaching Hospital, AP-HP, Créteil, France.
authors.forename: Gaelle
authors.initials: G
authors.lastname: Derot
authors.forename: Andre
authors.initials: A
authors.lastname: Marini-Portugal
authors.forename: Bernard
authors.initials: B
authors.lastname: Maitre
authors.forename: Pascal
authors.initials: P
authors.lastname: Claudepierre
mesh_terms: D018501:Antirheumatic Agents / Q000008:administration & dosage; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy*; D018450:Disease Progression; D004334:Drug Administration Schedule; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D008168:Lung / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D055613:Multiple Pulmonary Nodules / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000276:immunology*; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept; D008727:Methotrexate